DongKook Pharmaceutical Co., Ltd.
086450.KQ - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.06T
Close$
$13137.49
46.4% downside
Current Fair Value
46.4% downsideOvervalued by 46.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.06 Trillion |
|---|---|
| Enterprise Value | $1.05 Trillion |
| Annual dividend | $200.00 |
| Dividend yield | 0.85% |
| Earnings per Share | $1487 |
| Beta | 0.02 |
| Outstanding Shares | 45,111,000 |
Return
| Return on Equity | 10.95% |
|---|---|
| Return on Assets | 6.83% |
| Return on Invested Capital | 12.33% |
Valuation & Multiples
| P/E Ratio | 13.8 |
|---|---|
| PEG | 122 |
| Price to Sales | 1.13 |
| Price to Book Ratio | 1.38 |
| Enterprise Value to Revenue | 1.07 |
| Enterprise Value to EBIT | 10.26 |
| Enterprise Value to Net Income | 13 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$264.33 B
Consensus analyst estimateNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$254.28 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About DongKook Pharmaceutical Co., Ltd.
1,306 employees
CEO: Heung-Ju Oh
DongKook Pharmaceutical Co., Ltd., established in Seoul, South Korea in 1968, operates as a pharmaceutical company with a broad presence both domestically and globally. Formerly known as UEC & Co., Ltd. until its rebranding in March 1982...